High-dose Bevacizumab in Advanced Renal Carcinoma Patients

Part of paid clinical trials in Fort Myers, Florida.

Sponsor
SCRI Development Innovations, LLC
Study ID
NCT00455975
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This trial will examine the effectiveness and the side effects of 2 higher dosing schedules of bevacizumab in patients that have advanced clear cell renal carcinoma.

Key Dates

First listed
Apr 4, 2007
Start date
Feb 28, 2007
Status verified
Dec 2014
Primary completion
Jul 31, 2013
Completion
Sep 30, 2013

Study Design

Enrollment
119 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Weekly Avastin
    Bevacizumab 15mg/kg IV weekly until progressive disease or toxicity
  • Experimental: Bi-weekly Avastin
    Bevacizumab 15mg/kg IV every 2 weeks until progressive disease or toxicity

Primary Outcome Measure

Progression-free Survival [ Time Frame: 18 months (expected) ]

Locations (13)

FacilityCityStateZIPSite coordinators
Florida Cancer SpecialistsFort MyersFlorida33901-
Northeast Georgia Medical CenterGainesvilleGeorgia30501-
Consultants in Blood Disorders and CancerLouisvilleKentucky40207-
Center for Cancer and Blood DisordersBethesdaMaryland20817-
Methodist Cancer CenterOmahaNebraska68114-
Cancer Care of Western North CarolinaAshevilleNorth Carolina28801-
Oncology Hematology CareCincinnatiOhio45242-
University of Pittsburgh Medical CenterPittsburghPennsylvania15213-
Spartanburg Regional Medical CenterSpartanburgSouth Carolina29303-
Chattanooga Oncology Hematology AssociatesChattanoogaTennessee37404-
Family Cancer CenterColliervilleTennessee38017-
Tennessee Oncology, PLLCNashvilleTennessee37023-
Peninsula Cancer InstituteNewport NewsVirginia23601-

Find similar trials in Fort Myers, FL

By condition
By specialty

Related Studies